z-logo
Premium
Active tuberculosis is characterized by an antigen specific and strictly localized expansion of effector T cells at the site of infection
Author(s) -
Nemeth Johannes,
Rumetshofer Rudolf,
Winkler HeideMaria,
Burghuber Otto C.,
Müller Catharina,
Winkler Stefan
Publication year - 2012
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.201242678
Subject(s) - biology , immunology , antigen , effector , immune system , mycobacterium tuberculosis , cytotoxic t cell , t cell , chemokine , cytokine , chemokine receptor , il 2 receptor , tuberculosis , in vitro , medicine , pathology , biochemistry
Mycobacterium tuberculosis ( MTB )‐specific cytokine responses in the peripheral blood and at the site of infection may differ significantly within the same individual, but the under‐lying T ‐cell subset changes are largely unknown. Here, we measured effector and memory T ‐cell markers on CD 4+ T cells ( CD 45 RO , cysteine chemokine receptor ( CCR )7, and CD 27) in peripheral blood and at the site of active tuberculosis ( TB ). Additionally, T cells were stimulated overnight with purified protein derivative ( PPD ) and early secretory antigenic target ( ESAT )‐6 to determine which T ‐cell subset produces MTB ‐specific interferon ( IFN )‐γ. A striking decrease in CCR 7 and CD 27 expression on T cells was noted at the site of active TB . Likewise, IFN ‐γ expressing, ESAT ‐6 specific CD 4+ CD 45 RO + CD 27− T cells were dramatically increased at the site of infection but were not detectable in peripheral blood. An antigen‐specific expansion of differentiated T cells at the site of active TB infection was poorly reflected in peripheral blood. Insight in these changes in MTB ‐specific effector T cells in different compartments of the body could lead to new approaches for immune‐based diagnosis and interventions.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here